Abstract: AIM: To observe the association between CYP2D6^*10 and CYP2C19^*2 genotype polymorphism and survival of breast cancer patient receiving tamoxifen (TAM) treatment.METHODS: 171 cases of breast cancer patient receiving TAM treatment were selected from breast surgery and medical oncology since 2004-2009. The service condition of TAM treatment and the survival state were examined, the paraffin section of patients were collected and used in DNA extract, the CYP2D6^*10 and CYP2C19^*2 genotype polymorphism were detected by PCR, and the association between CYP2D6^*10 and CYP2C19^*2 genotype polymorphism and survival of breast cancer patient receiving TAM treatment were ascertained.RESULTS: Overall survival (OS) of CYP2D6Wt/Wt, CYP2D6Wt/^*10 and CYP2D6^*10/^*10 were very similar (P>0.05). 5 years-OS of CYP2C19^*2/^*2 were significantly higher than that of CYP2C19 Wt/Wt group, and the difference was statistically significant (P<0.05); 10 years-OS of CYP2C19^*2/^*2 were significantly higher than that of CYP2C19 Wt/Wt or CYP2C19 Wt/^*2,and the difference was statistically significant (P<0.05); 5 or 10 years-OS of CYP2C19 Wt/Wt was similar to that of CYP2C19 Wt/^*2 (P>0.05).CONCLUSION: The CYP2D6^*10 genotype polymorphisms isn't associated with survival of breast cancer patient receiving TAM treatment. The CYP2C19^*2 genotype polymorphism is associated with survival of breast cancer patient receiving TAM treatment. The survival rate of breast cancer patient with CYP2C19^*2/^*2 receiving TAM treatment is the highest, that of CYP2C19 Wt/^*2 is medium, and that of CYP2C19 Wt/Wt is lower.

Key words: CYP2D6^*10, CYP2C19^*2, breast cancer, tamoxifen